Lantheus (NASDAQ:LNTH) Stock Price Expected to Rise, B. Riley Financial Analyst Says

Lantheus (NASDAQ:LNTH) had its target price boosted by equities researchers at B. Riley Financial from $97.00 to $129.00 in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. B. Riley Financial’s price target would indicate a potential upside of 22.11% from the company’s previous close.

Several other research analysts have also recently commented on LNTH. The Goldman Sachs Group reiterated a “neutral” rating and issued a $94.00 target price on shares of Lantheus in a report on Thursday, May 7th. Weiss Ratings restated a “hold (c)” rating on shares of Lantheus in a report on Tuesday, May 26th. Citizens Jmp restated a “market outperform” rating and issued a $115.00 price target on shares of Lantheus in a research report on Monday, June 29th. Mizuho raised their price objective on shares of Lantheus from $100.00 to $115.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 27th. Finally, William Blair restated an “outperform” rating on shares of Lantheus in a report on Tuesday, March 17th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $108.29.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $105.64 on Thursday. The stock’s fifty day simple moving average is $100.71 and its 200 day simple moving average is $82.90. The stock has a market capitalization of $6.88 billion, a price-to-earnings ratio of 25.46 and a beta of -0.06. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. Lantheus has a 52-week low of $47.25 and a 52-week high of $111.86.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, beating the consensus estimate of $1.25 by $0.21. The business had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.Lantheus’s revenue was up 1.2% compared to the same quarter last year. During the same period in the prior year, the business posted $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, sell-side analysts forecast that Lantheus will post 4.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Western Wealth Management LLC acquired a new position in Lantheus in the 1st quarter valued at approximately $25,000. Smartleaf Asset Management LLC boosted its stake in shares of Lantheus by 63.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 197 shares during the period. Parallel Advisors LLC boosted its stake in shares of Lantheus by 122.6% during the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 298 shares during the period. Osterweis Capital Management Inc. purchased a new position in shares of Lantheus during the 2nd quarter valued at $36,000. Finally, Bessemer Group Inc. grew its holdings in shares of Lantheus by 221.2% during the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 354 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.